BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Assess the Pharmacodynamics (PD) of Prednisoline in Healthy Male Subject

Phase 1

Completed

Conditions: Immunoscience

Interventions: Drug: Prenisolone
Drug: Placebo

First Posted Date: 2017-06-22

Last Posted Date: 2019-12-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT03196557

Locations: 🇺🇸
Ppd Development, Austin, Texas, United States
🇺🇸
Local Institution, Austin, Texas, United States

A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia

Phase 3

Completed

Conditions: Lung Cancer
Non-Small Cell Lung Cancer

Interventions: Biological: Nivolumab

First Posted Date: 2017-06-22

Last Posted Date: 2024-07-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 400

Registration Number: NCT03195491

Locations: 🇹🇭
Local Institution, Khon Kaen, Thailand
🇨🇳
Local Institution - 0017, Changsha, Hunan, China

Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment

Phase 1

Completed

Conditions: Thrombosis

Interventions: Drug: BMS-986177

First Posted Date: 2017-06-22

Last Posted Date: 2022-06-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT03196206

Locations: 🇺🇸
Clinical Pharmacology of Miami LLC, Miami, Florida, United States
🇺🇸
Clinical Pharmacology Of Miami Inc., Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)

Phase 3

Withdrawn

Conditions: Giant Cell Arteritis

Interventions: Other: Placebo
Drug: Abatacept
Drug: Glucocorticoid Treatment

First Posted Date: 2017-06-20

Last Posted Date: 2017-07-12

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03192969

Locations: 🇬🇧
Local Institution, London, United Kingdom

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: BMS-986205
Biological: Nivolumab

First Posted Date: 2017-06-20

Last Posted Date: 2019-04-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 11

Registration Number: NCT03192943

Locations: 🇯🇵
Local Institution, Chuo-ku, Tokyo, Japan

A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Rivaroxaban
Drug: Dabigatran
Drug: Apixaban
Drug: Warfarin

First Posted Date: 2017-06-16

Last Posted Date: 2019-01-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36000

Registration Number: NCT03189069

A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2017-06-15

Last Posted Date: 2023-06-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 171

Registration Number: NCT03188081

Locations: 🇮🇹
Local Institution, Brescia, Italy

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Pancreatic Cancer
Colorectal Cancer

Interventions: Drug: Nab-paclitaxel
Drug: BMS-813160
Drug: 5-fluorouracil (5-FU)
Biological: Nivolumab
Drug: Gemcitabine
Drug: Leucovorin
Drug: Irinotecan

First Posted Date: 2017-06-14

Last Posted Date: 2023-07-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 332

Registration Number: NCT03184870

Locations: 🇺🇸
Local Institution - 0004, Hackensack, New Jersey, United States
🇺🇸
Local Institution - 0033, Boston, Massachusetts, United States
🇺🇸
Local Institution - 0027, Rochester, Minnesota, United States

and more 37 locations

Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults

Completed

Conditions: Hepatitis C

Interventions: Other: Non-Interventional

First Posted Date: 2017-06-08

Last Posted Date: 2020-03-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 10

Registration Number: NCT03181074

Locations: 🇲🇽
Local Institution, Mexico, D.f., Distrito Federal, Mexico

A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan

Completed

Conditions: Melanoma

Interventions: Other: Non-Interventional

First Posted Date: 2017-05-24

Last Posted Date: 2019-10-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 68

Registration Number: NCT03165422

Locations: 🇯🇵
Local Institution, Minato-ku, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy